CompletedPhase 1NCT02771340

Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma

Studying Uveal melanoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Iconic Therapeutics, Inc.
Principal Investigator
Gabriela Burian, MD
Iconic Therapeutics, Inc.
Intervention
ICON-1(biological)
Enrollment
10 target
Eligibility
18 years · All sexes
Timeline
2016 – 2017

Study locations (8)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02771340 on ClinicalTrials.gov

Other trials for Uveal melanoma

Additional recruiting or active studies for the same condition.

See all trials for Uveal melanoma →

← Back to all trials